Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PF1801

            Therapeutic Area: Genetic Disease Product Name: PF1801

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: PhaseBio Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2021


            Immunoforge is developing agents for rare muscle related diseases, such as Duchenne muscular dystrophy, polymyositis, and inclusion body myositis, based on its patent with PF1801 from PhaseBio, which has completed phase 2 clinical trials.